Taken together, this study provides insights into how these cancers, particularly those with high levels of basal oxidative stress, might be targeted in the future by extending the use of PARP-trapping drugs via the exploitation of ROS-potentiated replication stress [63]. Here, PARP1 is linked to cancer.